Introduction: The aldosterone/renin ratio (ARR) is the first line screening test for primary aldosteronism (PA). However, in hypertensive patients with an increased ARR, PA needs to be confirmed by other means. Methods: A 25 mg oral captopril test was performed in 16 healthy subjects to obtain reference values for aldosterone and ARR at 120 minutes after the test. Subsequently these data were applied to 46 hypertensive patients screened for PA with an increased ARR. Results: At 120 minutes after the captopril test ARR decreased in healthy subjects within a narrow range, but remained high in patients with PA and in patients with primary hypertension, especially for those with low renin characteristics. At 120 minutes after captopril, the range of ARR in primary hypertensive patients overlapped in 88% of the cases with the range of the ARR in the PA patients. Sensitivity and specificity of basal ARR and ARR after the captopril test to diagnose PA, calculated as receiver operator characteristics, showed an area under the curve of 0.595 for basal ARR and 0.664 for ARR at 120 minutes after the test. Conclusion: The ARR at 120 minutes after the captopril test is only marginally better than basal ARR in diagnosing PA in hypertensive patients screened with an increased ARR. Owing to an overall limited capacity to clearly discriminate PA from primary hypertension, the test could not therefore be recommended for the confirmatory diagnosis of PA.
Introduction
Primary aldosteronism (PA) is characterised by hypertension, metabolic alkalosis, increased aldosterone levels and low renin concentrations. [1] [2] [3] [4] PA was first described in 1955, 5 and is now recognized as a fairly common cause of secondary hypertension, 1-2, 6-9 accounting for up to 5-10% of all hypertensive patients. 7, 8, 10, 11 The aldosterone to renin ratio (ARR) is currently the most widely recommended first line screening test for PA. [11] [12] [13] [14] [15] [16] However, since the specificity of the ARR is low, a high ratio indicative of PA needs to be confirmed by dynamic testing of the renin-angiotensin system. 3, 17 Currently, recommended approaches to confirm PA comprise insufficient suppression of aldosterone secretion after volume expansion, using oral sodium load, saline infusion or fludrocortisone, or by a lower than normal inhibition of the renin-angiotensin aldosterone system by captopril. 3, 18, 29, 30, 32 No general consensus has been reached as to which test is superior. At some centres, however, volume expansion using fludrocortisone or oral sodium load is considered the most reliable method. 15, 17, 19, 20, 21, 31 According to earlier experience, the fludrocortisone test can be performed with 500 mg NaCl daily. 17 A cut off level of serum aldosterone at 305 pmol/L after 3 days or 225 pmol/L after 4 days (using the DPC aldosterone method) has been established. 17 However, the disadvantages of saline infusion, oral sodium loading and the fludrocortisone test are volume overload and, following fludrocortisone, also hypokalaemia. Therefore, these protocols raise some concern for application in an outpatient setting. 2, 3, 15, 19 The evaluation of the captopril test has previously been based on the suppression of the serum concentration of aldosterone. 18, [21] [22] [23] In healthy subjects the decrease of aldosterone and the increase of renin concentrations after inhibition of angiotensin converting enzyme (ACE), leads to a decrease in ARR. In theory the application of the post captopril ARR in the diagnosis of PA should therefore improve the accuracy of the test.
The present study was designed to reassess the value of the captopril test in the diagnosis of PA, using not only the suppression of aldosterone, but also ARR at the end of the test, analysed with modern analytical direct methods for aldosterone and renin concentrations. Due to lack of data regarding the biomedical outcome of captopril suppression in the healthy subjects, the test was performed in 16 healthy subjects to obtain reference values for aldosterone and ARR before and after the captopril test. The reference values for aldosterone and ARR at 120 minutes after the captopril test obtained from healthy subjects were subsequently applied in the evaluation of the test in hypertensive patients screened for PA in primary care with an increased ARR.
Material and methods Ethics
The Ethics Committee of the Faculty of Medicine, Lund University, approved the study. After medical examination and written and oral information, an informed consent was obtained from healthy subjects and patients.
Study design
Healthy subjects. Sixteen healthy subjects, 10 women, age 23-55 years, and 6 men, age 21-36 years, were recruited among medical students and hospital employees. All subjects had normal blood pressure. No medication was allowed except for intrauterine device.
Hypertensive patients screened for PA. In total, 101 hypertensive patients were screened for PA in primary care using ARR. Of these, 55 patients had a normal ARR. The plasma levels of potassium in these patients ranged from 3.2 to 4.4 mmol/L. The mean level of serum aldosterone was 287±152 pmol/L and the mean value of plasma renin was 10.9±14.3 mIU/L.
Patients with suspected PA at primary care screening. Forty-six of 101 patients with hypertension, 27 women with a median age of 62 years (range 36-75 years) and 19 men with a median age of 62 years (range 40-75 years), were referred with the suspicion of PA due to an increased ARR at screening in primary care. 10 The duration of known hypertension for the patients ranged between 1 and 20 years. The median value for plasma potassium was 3.8 mmol/L (range 3.3-4.4 mmol/L). The mean blood pressure measured in sitting position was 160/95 mmHg.
The captopril suppression test
Patients were subjected to the captopril test at the Department of Endocrinology. Antihypertensive drugs known to interfere with the aldosterone-renin axis, such as beta-blockers, diuretics, ACE-inhibitors and angiotensin II-antagonists were withdrawn two weeks before the test. Blood pressure was measured at least once during the withdrawal period. Plasma potassium was measured and evaluated prior to testing.
The captopril test was performed in the morning after resting for 30 minutes with the studied subject in a seated position. Blood samples for serum aldosterone and plasma renin were drawn immediately before the patient received 25 mg of captopril orally and subsequently during 120 minutes. The 120 minute samples were used for test evaluation. Blood pressure was measured with a jewel movement sphygmomanometer before the test, at 60 minutes, and at the end of the test (120 minutes).
Handling of blood samples
Blood samples were centrifuged at room temperature. Plasma and serum were frozen at -20°C with the exception of samples for sodium, potassium and creatinine, which were analysed the same day with a routine auto analyser. All blood samples for aldosterone and renin from each group were analysed in the same run.
Biochemical methods
Serum aldosterone concentration was determined with the DPC-method (Aldosterone Coat-A-Count, DPC, California, USA). Total inter assay coefficients of variation (CVs) for this method are 8.7% and 8.9% at 90 and 725 pmol/L respectively. The reference interval for serum aldosterone in the morning in the standing position is 110-860 pmol/L. Plasma renin concentration was determined with the direct method from Cis-Bio (Renin III generation, Cis-Bio International, France). The CVs for this method are 4.4% and 3.7% at 27 and 100 mIU/L respectively. The reference range for morning samples is 4-64 mIU/L. The reference range in our laboratory for morning samples of ARR using the aldosterone method from DPC and the renin method from Cis-Bio is 4-65 pmol/mIU. Plasma concentrations of creatinine, sodium and potassium were determined through routine methods on Hitachi Modular P (Roche Diagnostics, Mannheim, Germany). The reference ranges for plasma sodium, plasma potassium and plasma creatinine are 136-146 mmol/L, 3.2-4.7 mmol/L and 50-100 umol/L respectively.
Diagnosis of primary aldosteronism. Fourteen of the patients were diagnosed with PA. The diagnosis of PA was confirmed by fludrocortisone suppression test (FST; fludrocortisone 0.1 mg 4 times daily for 4 days 17 ) and the subtype classification by adrenal CT scan and sequential bilateral adrenal vein sampling (AVS). For adequate catheter position, a cortisol gradient at 2.5-3 between the adrenal and peripheral veins was required. For lateralisation, the aldosterone / cortisol concentration quotient should be > 2.5 times higher in the adrenal vein compared with the peripheral vein. Preferably, the aldosterone / cortisol concentration quotient should be < 1 in the contra-lateral adrenal vein, indicating suppression of the aldosterone secretion. In 32 patients, the suspicion of PA was not verified since the FST was negative and they were thus diagnosed with primary hypertension, according to the same diagnostic protocol.
The diagnosis of PA due to an adrenal aldosteronoma was histologically verified after robot-assisted unilateral adrenalectomy in six patients. These patients were preoperatively evaluated by CT scanning demonstrating a tumour between 8 mm and 20 mm in size, and by AVS that showed lateralisation of aldosterone secretion. On admission, the plasma potassium level for these patients ranged between 2.5 and 3.4 mmol/L. Five of the patients had a normalization of their blood pressure after surgery and one patient had a reduction of hypertensive medication.
Among eight patients diagnosed with PA due to adrenal hyperplasia, CT scanning was normal in four patients and showed a wide adrenal limb in four cases. Adrenal venous sampling was performed in four patients without lateralisation of aldosterone secretion. The FST 17 was performed in three patients with confirmatory result for PA; one patient refused testing, one patient was previously diagnosed with PA and, in three patients, the test was not performed due to severe hypertension. On admission, plasma potassium levels in these patients ranged from 2.6 to 4.0 mmol/L. The eight patients were treated with an mineralocorticoid receptor antagonist with a convincing effect on the patients' blood pressure, further supporting the diagnosis.
In the remaining group of 32 patients, support for the diagnosis of PA was not achieved since they had a negative FST during workup and a diagnosis of primary hypertension was assumed. However, in these 32 patients low renin characteristics were sometimes noted.
For the main comparison, patients with PA due to adenoma or hyperplasia were analysed as one group. Basal and 120 minute values for aldosterone, renin and ARR were compared.
Statistics
Statistical analyses were carried out using SPSS for Windows, version 14.0. Values for aldosterone, renin and ARR are given as mean (± SD) if not stated otherwise.
As a normal distribution could not be established and as sample sizes were small in some instances, non-parametric methods were used throughout. Analysis of differences between groups was performed using the Kruskal-Wallis test and subsequently the Mann-Whitney U test. For comparisons within groups between baseline and 120 minutes, the Wilcoxon signed rank test was applied. Due to multiple comparisons the Bonferroni correction was applied. A p-value of < 0.05 was considered statistically significant.
For comparison of ARR between groups before (basal), and at 120 minutes after the captopril test, sensitivity and specificity was calculated as area under the curve (AUC) for receiver operating characteristics (ROC), using confirmed aldosteronism (PA; n = 14) as the dependent variable and ARR as the independent variable. AUC = 1.00 indicates complete separation.
Results
The captopril suppression test was well tolerated, causing neither hypotension nor clinically relevant changes in potassium levels among patients and healthy subjects. Furthermore, no other side effects were reported.
Healthy subjects
There were significant changes in aldosterone (p < 0.001), renin (p = 0.016) and ARR (p < 0.001) at 120 minutes after the captopril test (table 1) . Aldosterone decreased in 14 of 16 subjects. Renin increased in 10 subjects, decreased in 3 and was stable in 3 subjects (table 1) . ARR decreased in 15 subjects (table 1, figure 1 ).
Effects of captopril within the studied patient groups
Patients with PA due to aldosteronoma or adrenal hyperplasia (n = 14). Aldosterone decreased significantly (p = 0.005) (table 1) while renin remained low after the captopril test (p = 0.844) (table 1). At 120 minutes after captopril, ARR was not significantly different from the basal value (p = 0.096) (table 1). An ARR of more than > 130 pmol/ mIU 120 minutes after the captopril test was only observed in patients with aldosteronoma.
Primary hypertension (not verified suspicion of PA: n = 32).
After the captopril test, aldosterone levels decreased significantly (p < 0.001) (table 1), while renin increased slightly but remained at low concentrations (p = 0.035) (table 1). ARR decreased moderately (p < 0.001) (table 1) .
Comparison between groups before and at 120 minutes after the captopril test. Compared with healthy subjects, basal aldosterone was higher in PA patients (p = 0.010) but not in patients with primary hypertension (table 1) . At 120 minutes after captopril, aldosterone tended to be lower in patients with primary hypertension compared with patients with PA (p = 0.088).
Before the captopril test, plasma renin concentration did not differ between patients with PA and patients with primary hypertension, but was lower in both than in healthy subjects (table 1) . After the captopril test, renin remained low in patients with PA (p < 0.001) and in patients with primary hypertension (p = 0.006) compared with healthy subjects.
Basal ARR did not differ between patients with PA and primary hypertensive patients (p = 0.310) nor at 120 minutes after captopril was the ARR different between these groups (p = 0.079).
Sensitivity/ specificity of basal ARR and ARR after the captopril test
Patients with primary hypertension (n = 32) vs patients diagnosed with PA (n = 14). The ROC curves for basal ARR and ARR at 120 minutes after the captopril test are shown in figure 2 and figure 3 . The AUC calculated from the ARR as the independent variable was 0.595 (Standard Error 0.103) at baseline and 0.664 (Standard Error 0.101) at 120 minutes after captopril, indicating a low capacity to separate between patients with primary hypertension and patients with PA.
Discussion
The conclusion of the present study is that the captopril test is not reliable as a confirmatory test in the diagnosis of PA. The test does not distinguish between patients with PA and patients with primary hypertension already screened with a high ARR. The specificity of the test is low to moderate, and although the ARR at 120 minutes after the captopril test had less widely distributed values compared with basal ARR, from a clinical point of view, the sensitivity and specificity does not differ. Furthermore, we found ARR to perform better than aldosterone among the healthy subjects and therefore chose ARR for the present evaluation of the captopril test. A limitation of our study could be that the reference ranges obtained might have been different if the healthy subjects had been recruited among subjects with similar ages as the hypertensive patients studied. The aldosterone concentrations ranged between 91 and 816 pmol/L after the captopril test in PA patients. The wide range is in accordance with previous observations of intermittent and highly variable aldosterone secretion among healthy subjects, 24, 25 and therefore creates inherent difficulties in establishing a cut off level for the diagnosis of PA. Thus, in recent consensus statements, no minimal basal aldosterone level could be defined for the diagnosis of PA. 3, 20 Thirty-two patients referred from primary care because of a high ARR did not fulfil the criteria for PA and were diagnosed with primary hypertension. A significant number of these patients showed low renin concentrations with poor response to ACE inhibition, suggesting a disturbance in the renin-angiotensin-aldosterone system, similar to 'low-renin hypertension'. 26 Low renin has a greater impact than high aldosterone level on ARR. Various factors affect the renin secretion, of which pharmaceuticals have the greatest effect. Therefore, care had been taken in the present study to avoid renin suppressive drugs.
The present evaluation and comparison of the aldosterone-renin characteristics illustrated a gradual disturbance appearing in some patients with hypertension. Awareness of this seems to be of great importance in the interpretation of the captopril test as some patients with low renin otherwise would be falsely classified as having PA. Notably, a similarity between renin and aldosterone secretion in patients formerly characterised as having low-renin hypertension and PA patients with adrenal hyperplasia has previously been suggested. [26] [27] [28] Some patients diagnosed as primary hypertensives might have a suppressed renin level and be less responsive to inhibition of the ACE by captopril. On the other hand, some aldosteronomas have preserved sensitivity to angiotensin II 19 and are therefore responsive to captopril, leading to decreased aldosterone concentration and decreased ARR. This reaction to ACEinhibitors could contribute to the low specificity of the captopril test as pointed out in previous guidelines and studies. 3, 21, 27 These observations, together with the results from the present study, are of importance for the understanding of the limitations of the captopril test to discriminate between PA and primary hypertension, highlighted by the high frequency of increased ARR in the screening setting. 3, 20 However, an ARR at 120 minutes within the obtained normal range based on test results in healthy subjects strongly argues against PA. On the other hand, a high ARR (> 130 pmol/mIU) after captopril not only supports the diagnosis of PA, but also suggests the possibility of an aldosterone secreting adrenal adenoma.
Conclusions
• Basal ARR and ARR at 120 minutes after captopril show poor discriminatory capacity for the diagnosis of PA in hypertensive patients screened with high ARR.
• Volume expansion, for instance by fludrocortisone or oral sodium load, remains the gold standard for the differential diagnosis of PA in hypertensive patients. However, the impact of low-renin hypertension on these tests remains to be investigated.
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